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INTRODUCT ION
The wide use of opiate drugs as analgesics is based on
their good efficacy in different clinical settings. In
particular, l-opioid receptor agonists are included in
two of the three steps of the ladder for the control of
chronic pain proposed by the WHO and are widely
prescribed for the treatment of pain associated with
cancer processes. It is well established that the analgesic
effect induced by opioids can vary depending on the type
of injury, as demonstrated both in humans and in
laboratory animals. Thus, the analgesic effects induced
by systemic morphine have been shown to be decreased
in neuropathic states [1], while in animals bearing
inflammatory processes they are generally enhanced [2–
4]. Several mechanisms seem to be involved in the
amplification of opiate analgesia during inflammation
[3,5–7]. Among them, we have recently described that
the increased analgesic effect of morphine measured by a
thermal test in carrageenan-inflamed mice can be related
to the amplification of the spinal effects triggered by Gi/o
proteins and GIRK channels [8].
The inhibition of different behavioral nociceptive
symptoms evoked by systemic morphine has been also
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Agonists?of?l-opioid?receptors?are?currently?used? in? the?management?of?cancer?pain.?
However,? several? data? suggest? that? the? analgesic? effect? of?morphine? can? diminish?
during? the? development? of? experimental? tumors.? By? using? a? thermal? test,?we? have?
studied?whether?the?analgesic?effect?evoked?by?morphine?is?altered?in?mice?bearing?two?
painful? bone? tumors.? The? analgesic? effect? evoked? by? systemic? morphine? remained?
unaltered? after? the? intratibial? inoculation? of? B16-F10? melanoma? cells? and? was?
potentiated? after? the? inoculation? of? NCTC? 2472? osteosarcoma? cells.? Although? the?
number? of? spinal? l-opioid? receptors? measured? by? western? blot? studies? was? not?
augmented? in? osteosarcoma-bearing?mice,? the? analgesia? evoked? by? intrathecal? (i.t.)?
morphine? was? also? enhanced.? The? analgesic? response? produced? by? the? spinal?
administration?of? the?Gi/o?protein? activator?mastoparan?was?amplified,?whereas? the?
analgesic? response? evoked? by? the? i.t.? administration? of? the?N-type? calcium? channel?
blocker?x-conotoxin? remained? unaltered.? The? efficacy? of? the? GIRK? channel? blocker?
tertiapin-Q? to? antagonize? the? analgesic? effect? produced? by? a? maximal? dose? of?
morphine? was? also? increased? in? osteosarcoma-bearing? mice.? Our? results? seem? to?
indicate?that?the?analgesic? effect?of?morphine?on?thermal?nociception?can?be?enhanced?
in? response? to? the? development? of? particular? bone? tumors? in? mice,? being? this?
potentiation?probably? related?to?a?greater?efficacy?of?the?transduction?system?driven?by?
Gi/o?proteins?and?GIRK?channels.
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studied in several bone cancer models. Thus, by using
some variants of the painful tumor based on the
intraosteal inoculation of NCTC 2472 fibrosarcoma cells,
it was reported that systemic morphine reduces sponta-
neous flinches and guarding behavior [9,10], thermal
and mechanical hyperalgesia [10,11], or mechanical
allodynia [9,12,13] as well as normalizes the decreased
grip force of the affected limbs [14], and similar data
have been obtained in other models further developed by
administering different tumoral cell types in mice and
rats. The majority of the referred data indicate that the
doses of morphine necessary to evoke acute analgesic
effects in tumor-bearing rodents are rather high (10–
50 mg/kg) when compared to those active in other
painful experimental situations or in healthy animals.
However, some few reports describe the inhibition of
particular neoplastic nociceptive symptoms by doses of
morphine comparable to those useful to counteract pain
symptoms linked to inflammatory processes. Thus, doses
below 10 mg/kg reduce the spontaneous paw lifting and
restore the use of the affected limb in mice inoculated
with NCTC 2472 cells into the femur [10] and inhibit
mechanical allodynia in tumor-bearing rats [15]. Final-
ly, doses of morphine as low as 1–3 mg/kg are effective
to counteract mechanical hyperalgesia in rats intratibi-
ally inoculated with different tumoral cells [16,17].
During the past years, we have performed behavioral
studies with two different models of murine bone
cancer-induced pain, based on the intratibial inocula-
tion of either fibrosarcoma NCTC 2472 cells, which
evokes the growth of an osteoclastic tumor [11], or
melanoma B16-F10 cells, which leads to the develop-
ment of a mixed osteoclastic/osteoblastic bone tumor
accompanied by an earlier instauration of hyperalgesia
and allodynia [18]. In the present study, we explore
whether changes in the analgesic effect evoked by
systemic morphine occur in these two different murine
neoplastic settings. We had previously described that
the systemic administration of a high dose of morphine
(15 mg/kg) completely prevented osteosarcoma-induced
thermal hyperalgesia, increasing thermal withdrawal
latencies of both hind paws up to cutoff values [11].
However, the range of active doses of morphine had not
been described in this former paper and, related to mice
inoculated with B16-F10 cells, the efficacy of systemic
morphine has not been still explored. In this context, we
study here whether differences in the analgesic potency
of systemic morphine, assessed by measuring thermal
latencies, appear in mice bearing each of the above-
mentioned bone tumors. Furthermore, as we detected
that the analgesic effect of morphine is dramatically
enhanced in one of these models, we have tried to
elucidate whether some functional alterations in spinal
Gi/o proteins and GIRK channels participate in the
amplification morphine analgesia measured in these
tumor-bearing mice, as previously described in carra-
geenan-inflamed mice [8].
MATER IALS AND METHODS
Animals
The experiments were performed in 5- to 6-week-old
male C3H/He and C57BL/6 mice bred in the Animalario
de la Universidad de Oviedo (Reg. 33044 13A), main-
tained on a 12-h dark–light cycle with free access to food
and water. Experimental procedures were approved by
the Comite´ E´tico de Experimentacio´n Animal de la
Universidad de Oviedo (Asturias, Spain). Each animal
was used only once.
Drugs and drug administration
Morphine hydrochloride (Ministerio de Sanidad, Madrid,
Spain), the Gi/o protein activator mastoparan (Tocris),
the N-type Ca2+ channel blocker x-conotoxin GVIA
(Tocris), and the GIRK channel blocker tertiapin-Q
(Tocris) were used. Drugs were dissolved in saline.
For intrathecal (i.t.) injections, a slight modification of
the original method [19] was used. Briefly, a lumbar cut
was made, and the tip of a 30-gauge needle inserted in a
Hamilton microsyringe was introduced at the level of
L5–L6 to inject a volume of 5 lL [8].
Cell inoculation
NCTC 2472 osteosarcoma cells and B16-F10 melanoma
cells (ATCC) were cultured and passaged weekly as
previously described [11,18]. Cells were detached by
scraping and centrifuged, and the remaining pellet
suspended in PBS. For surgical procedures, anesthesia
was induced by spontaneous inhalation of 3% isoflurane
(Isoflo; Esteve, Barcelona, Spain) and maintained by
administering 1.5% isoflurane in oxygen through a
breathing mask. A suspension of 105 cells in 5 lL of
PBS was injected into the right tibial medullar cavity and,
after applying acrylic glue (Hystoacril; Braun, Barce-
lona, Spain) on the tibial plateau incised area, surgerywas
finished with a stitch of the skin. Control mice were
inoculated with 105 cells killed by quickly freezing them
three times without cryoprotection. Thermal hyperalgesia
was studied 4 weeks after the inoculation of NCTC 2472
cells [11] and 1 week after B16-F10 cell inoculation [18].
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Unilateral hot plate
Mice were gently restrained, and the plantar side of the
tested paw was placed on the hot plate surface
(52.5 ± 1 C) [20]. Measurements of withdrawal laten-
cies from the heated surface of each hind paw were made
separately at 2-min intervals, and the mean of two
measureswas considered. A cutoff of 30 swas established.
Experiments were performed between 15:00 and 20:00
in a thermostatized (21 C) and noise-isolated room.
Western blot assays
Four weeks after NCTC 2472 cell inoculation, mice were
exposed to CO2 and decapitated. Lumbar spinal cord was
extracted by flushing 1–2 mL of ice-cold saline through
the spinal cavity with a syringe, and L2–L6 lumbar
spinal segments were conserved at )80 C. Each sample
came from a unique animal.
As previously described [8], spinal cords were homo-
genized and the supernatant obtained after centrifugation
(26 000 g, 20 min, 4 C) was collected. Protein con-
centrations were determined by a BCA protein assay
(Pierce, Rockford, IL, USA). Samples (100 lg of protein
in 30 lL of buffer) were run on a 10% SDS-PAGE gel at
90 V and then transferred onto nitrocellulose (Bio-Rad,
Hercules, CA, USA) at 4 C during 90 min at 100 V. The
nitrocellulose membrane was blocked in Tris-buffered
saline–Tween with 5% non-fat milk for 90 min at RT,
washed, and incubated overnight at 4 C with rabbit
polyclonal anti-l-opioid receptor (1 : 2000; Chemicon,
Billerica, MA, USA). After incubation, the membrane
was washed and incubated with the secondary antibody
(anti-rabbit Ig G, 1 : 14000; Sigma) in the presence of
0.1% non-fat milk for 90 min. Labeled l-opioid receptor
protein was detected by enhanced chemiluminescence
detection autoradiography using Supersignal West Pico
Chemiluminiscent Substrate kit (Pierce). Immune reac-
tion intensity was determined by computer-assisted
densitometry (ImageJ, NIH, Bethesda, MD, USA).
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH),
a constitutively expressed protein of 35 kDa, was also
measured using a polyclonal rabbit anti-mouse GAPDH
antibody (1 : 30000; Sigma, St. Louis, MO, USA). Results
are reported as the ratio of optical densities of l-opioid
receptor and GAPDH by normalizing the amount of
l-opioid receptor to the immunoreactivity of GAPDH.
Statistical analysis
Mean values and their corresponding standard errors
were calculated. Intergroup comparisons in the dose–
effect curves were made by an initial one-way analysis
of variance followed by the Dunnett’s t test. Compari-
sons of western blot data were made by the Student’s
t-test.
ED50 values were calculated by constructing quantal
dose–effect curves with the computer program Pharm
Tools Pro (version 1.27; The McCary Group Inc.,
Schnecksville, PA, USA). This parameter represents
the dose that yields analgesia in 50% of mice. A latency
value was considered to be analgesic when it surpassed
the 50% of the maximal analgesic effect. The 50% of the
maximal analgesic effect was calculated considering the
latency value obtained in the left paw of each group of
mice in basal conditions and the cutoff established in
30 s. Thus, in a prototypical case in which basal
latencies in non-inflamed paws is 14 s, the latency
corresponding to the 50% of maximal analgesic effect
should be 22 s. Comparisons between ED50 values were
made by an ANOVA. In all cases, statistical significance
was considered at P < 0.05.
RESULTS
Increase in thermal withdrawal latencies evoked by
systemic morphine in mice intratibially inoculated
with NCTC 2472 or B16-F10 cells
In mice inoculated with killed cells, withdrawal latencies
of both hind paws were measured. However, as values
obtained in both paws were almost identical, only those
corresponding to their right paws were analyzed in all
experiments.
The s.c. administration of morphine to C3H/He mice
inoculated with killed NCTC 2472 cells produced dose-
dependent analgesia, being 1.7 mg/kg the lowest dose
assayed able to significantly increase withdrawal laten-
cies and 5 mg/kg the one producing the maximal
analgesic response (Figure 1a). The calculated ED50 in
the right paw was 2.75 ± 0.17 mg/kg.
Thermal hyperalgesia detected in the affected (right)
hind paw of mice inoculated with live NCTC 2472 cells
was inhibited by the s.c. injection of doses of morphine as
low as 0.1 mg/kg. Remarkably, doses higher than
0.1 mg/kg produced an enhanced analgesic effect com-
pared with that obtained in mice inoculated with killed
cells not only in the injured one but in both hind paws.
Maximal analgesia was observed after the administration
of 1 mg/kg of morphine (Figure 1b). The calculated ED50
was 0.492 ± 0.11 mg/kg in the left paw and 0.495 ±
0.124 mg/kg in the right one.
The potency of morphine in C57BL/6 mice inoculated
with killed B16-F10 cells (Figure 1c) was similar to
3
that observed in C3H/He mice. Thus, analgesic
responses appeared at doses higher than 1 mg/kg,
being the maximal effect attained after the administra-
tion of 5 mg/kg of morphine and leading to an ED50
value of 2.44 ± 0.72 mg/kg. As represented in Fig-
ure 1d, when morphine was administered to C57BL/6
mice inoculated with live B16-F10 cells, no modification
of the potency of morphine to evoke analgesic effects
was observed although an antihyperalgesic effect after
the administration of 1 mg/kg of morphine was
detected. The calculated ED50 values were 3.7 ± 1.96
and 2.4 ± 0.98 mg/kg for the left and right paws,
respectively.
Increase in thermal withdrawal latencies evoked by
intrathecal morphine in mice intratibially
inoculated with NCTC 2472 cells
To elucidate whether osteosarcoma development en-
hances the analgesic effects produced by morphine at the
spinal cord, dose–response curves were constructed after
the i.t. administration of morphine to C3H/He mice
inoculated with either killed or live NCTC 2472 cells. The
i.t. administration of 0.5 lg of morphine produced a
significant increase in thermal withdrawal latencies of
mice inoculated with killed cells, being the maximal
analgesia reached after administering 1 lg of morphine
(Figure 2a). The ED50 was 0.529 ± 0.036 lg. In con-
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Figure 1 Analgesic effect induced by
systemic morphine in mice inoculated in
their right tibiae with killed (a) or live (b)
NCTC 2472 cells or killed (c) or live (d)
B16-F10 cells. Each point represents the
mean withdrawal latency value with its
corresponding standard error (n = 5–7).
*P < 0.05, **P < 0.01, compared with
saline-treated mice of each group,
Dunnett’s t test.
4
trast, in osteosarcoma-bearing mice, a dose of morphine
as low as 0.1 lg evoked a consistent effect and 0.5 lg
provoked maximal analgesia, leading to ED50 values of
0.16 ± 0.036 lg in the left paw and 0.19 ± 0.099 lg in
the right one (Figure 2b).
Measurement by western blot of spinal l-opioid
receptors expressed in mice inoculated with NCTC
2472 cells
Western blot experiments were performed in lumbar
spinal cord tissue from mice intratibially inoculated with
either killed or live NCTC 2472 cells. A band of 45 kDa,
compatible with the l-opioid receptors, was detected in
both cases (Figure 3a), although no difference in the
ratios of the l-opiod receptor and GAPDH expression was
found between mice inoculated with killed or live NCTC
2472 cells (Figure 3b).
Effects of the i.t. administration of the Gi/o protein
activator mastoparan on thermal withdrawal
latencies of mice inoculated with NCTC 2472 cells
The i.t. administration of 3 lg of mastoparan to mice
inoculated with killed NCTC 2472 cells produced a
significant analgesic effect that was maximal when 5 lg
was administered (Figure 4a). The calculated ED50 was
2.56 ± 0.75 lg.
An antihyperalgesic effect at low doses of mastoparan
and a potentiation of the analgesic effect of higher ones
were detected in osteosarcoma-bearing mice. Thus,
significant analgesia was induced in both paws after
the administration of 1 lg, and maximal analgesia was
attained after the administration of 3 lg (Figure 4b). The
calculated ED50 were 0.783 ± 0.277 and 0.98 ± 0.116
lg in the left and right paws.
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Figure 2 Analgesic effect induced by i.t.
morphine in C3H/He mice inoculated in
their right tibiae with killed (a) or live (b)
NCTC 2472 cells. Each point represents
the mean withdrawal latency value with
its corresponding standard error (n = 6).
*P < 0.05, **P < 0.01, compared with
saline-treated mice of each group, Dun-
nett’s t test.
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Figure 3 Expression of l-opioid receptors measured by western blot
in lumbar spinal cord segments of C3H/He mice intratibially
inoculated with NCTC 2472 cells. (a) Representative lanes of western
blot experiments performed in mice inoculated with killed (left panel)
or live (right panel) NCTC 2472 cells. Molecular weight markers
are indicated at the left side, and bands corresponding to l-opioid
receptor protein (at 45 kDa approximately) and GAPDH (at 35 kDa
approximately) are signaled with an arrow. (b) Fold change in
l-opioid receptors protein estimatedbyusing its correspondingGAPDH
as endogenous control in lumbar spinal cords of mice inoculated
with either killed or live cells. Data are the mean ± SEM (n = 5).
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Effects of the i.t. administration of x-conotoxin
GVIA on thermal withdrawal latencies of mice
inoculated with NCTC 2472 cells
The spinal administration of x-conotoxin GVIA produced
dose-dependent analgesia in mice inoculated with killed
cells, leading to an ED50 of 1.84 ± 0.165 ng (Figure 5a).
In osteosarcoma-bearing mice, lower doses of this drug
produced an antihyperalgesic effect in the injured paw
(Figure 5b). However, the ability of this drug to increase
withdrawal latencies above basal latency values was not
enhanced. ED50 values obtained in both paws of mice
inoculated with live NCTC 2472 cells were
2.225 ± 0.98 ng in the left paw and 3.23 ± 0.43 ng
in the right one.
Effects of the i.t. coadministration of the GIRK
inhibitor tertiapin-Q on the enhanced analgesia
evoked by i.t. morphine in mice inoculated with
NCTC 2472 cells
In mice inoculated with killed NCTC 2472 cells, the i.t.
coadministration of tertiapin-Q (75–250 ng) evoked a
dose-dependent inhibition of the maximal analgesia
evoked after the administration of 1 lg of i.t. morphine
(Figure 6a). The calculated ED50 value was 108 ±
13.3 ng.
The coadministration of tertiapin also reduced the
maximal analgesia evoked by the administration of
0.5 lg of morphine in mice inoculated with live NCTC
2472 cells (Figure 6b). A complete reversion occurred
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Figure 4 Analgesic effect induced by
i.t. administration of mastoparan in
C3H/He mice inoculated in their right
tibiae with killed (a) or live (b) NCTC
2472 cells. Each point represents the
mean withdrawal latency value with its
corresponding standard error (n = 6).
*P < 0.05, **P < 0.01, compared with
saline-treated mice of each group,
Dunnett’s t test.
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Figure 5 Analgesic effect induced by i.t.
administration of x-conotoxin in C3H/
He mice inoculated in their right tibiae
with killed (a) or live (b) NCTC 2472
cells. Each point represents the mean
withdrawal latency value with its
corresponding standard error (n = 6).
*P < 0.05, **P < 0.01, compared with
saline-treated mice of each group,
Dunnett’s t test.
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after the administration of 125 ng of tertiapin and ED50
values of 8.2 ± 3.5 and 6.1 ± 3.77 ng were obtained in
the left and the right paw, respectively.
DISCUSS ION
We show here, using a thermal test, that the effect of
systemic morphine in mice inoculated with B16-F10
cells is similar to that measured in mice without tumor
and that, strikingly, the effect of morphine is strongly
potentiated in mice inoculated with NCTC 2472 osteo-
sarcoma cells.
The inhibitory effect of systemic morphine on thermal
nociceptive reactions has been previously studied in
tumor-bearing mice after its acute administration [11] or
continuous perfusion [21]. Here, we have tested its
effects either 1 week after the inoculation of B16-F10
cells or 4 weeks after intratibial administration of NCTC
2472 cells, the corresponding times at which thermal
hyperalgesia can be detected in each case, as previously
described [11,18]. Our results show that morphine
induces analgesic responses in C57BL/6 mice receiving
the intratibial inoculation of B16-F10 melanoma cells at
doses similar to those effective in mice inoculated with
killed cells, being the potency of morphine indistinguish-
able in both cases. The result obtained in osteosarcoma-
bearing mice was surprising, because the doses of
morphine necessary to increase thermal withdrawal
latencies in both paws were significantly lower than
those effective in mice inoculated with killed cells. As
commented in the introduction, the information avail-
able indicated that the analgesic efficacy of morphine is
usually reduced in mice bearing neoplastic processes. An
obvious consideration to explain this discrepancy is the
influence of the method used to measure nociception.
Thus, whereas thermal or mechanical withdrawal
latencies can be augmented by the activation of periph-
eral opioid receptors in tumor-bearing mice, the response
to the stimulation with von Frey filaments remains
unaltered [18]. It seems then necessary to assume that
the present result cannot be generalized to other
nociceptive parameters. As we have previously described
the involvement of spinal mechanisms in the potentia-
tion of the analgesic effects induced by morphine in the
same thermal test in carrageenan-inflamed mice [8], we
tried to elucidate whether these mechanisms are also
implicated in the potentiation of morphine measured in
osteosarcoma-bearing mice.
In particular, the amplification of morphine-induced
analgesia observed in carrageenan-inflamed mice was
related to the stimulation of spinal opioid receptors,
independent on their upregulation, and mediated by the
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Figure 6 Effects of i.t. coadministration of tertiapin-Q on the analgesic effect produced by morphine in C3H/He mice inoculated in their right
tibiae with NCTC 2472 cells. (a) Inhibitory effect of tertiapin-Q on the analgesic effect induced by 1 lg of morphine in the right hind paws
of mice inoculated with killed NCTC 2472 cells. (b) Inhibitory effect of tertiapin-Q on the analgesic effect induced by 0.5 lg of morphine
measured in the left and the right paws of mice inoculated with live NCTC 2472 cells. Each point represents the meanwithdrawal latency value
with its corresponding standard error (n = 6). *P < 0.05, **P < 0.01, compared with morphine-treated mice of each group, Dunnett’s t test.
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amplification of Gi/o-GIRK transductional mechanisms
in the spinal cord [8]. The present experiments indicate
that these mechanisms also participate in the enhanced
effect of morphine measured in osteosarcoma-bearing
mice. Thus, the analgesic effect induced by morphine at
spinal level is also enhanced in mice inoculated with
NCTC 2472 cells, as demonstrated after its intrathecal
administration and, although a slight reduction in this
population of receptors has been previously found in
mice receiving the intrafemoral inoculation of NCTC
2472 cells [22], no change was found in the expression
of l-opioid receptors at the spinal level in our western
blot experiments.
The analgesia evoked by the spinal administration of
the Gi/o protein activator mastoparan [23] was also
potentiated in osteosarcoma-bearing mice although less
markedly than in inflamed mice [8]. Because analgesia is
attained after the administration of lower doses of
mastoparan in osteosarcoma-bearing mice than in
control ones, it may be conceived that the activation of
less Gi/o proteins is necessary to evoke analgesia in
osteosarcoma-bearing mice, as previously proposed in
inflamed mice [8]. In addition, the description that
mastoparan induces analgesic responses in cancer-bear-
ing mice suggests that the activation of Gi/o proteins
could perhaps represent a theoretical strategy to coun-
teract some painful symptoms related to these settings.
Considering that the analgesic effects of morphine at
the spinal cord can be mediated by opioid receptors
located at presynaptic or postsynaptic level, we have
tested whether the functionality of some of the main
targets modulated by morphine at presynaptic level,
such as N-type calcium channels [24], or postsynapti-
cally, such as G-coupled inwardly rectifying potassium
channels (GIRK) [25,26], would be altered in mice
bearing the osteosarcoma. The analgesic effect produced
after the spinal administration of the N-type calcium
channels blocker x-conotoxin GVIA was not potentiated
in mice inoculated with NCTC 2472 cells, thus suggest-
ing that an enhanced efficacy of these channels does not
participate in this potentiation. Related to spinal post-
synaptic mechanisms, it has been shown that the
analgesic effects induced by intrathecally administered
morphine is importantly linked to the activation of GIRK
channels [25] which are almost exclusively expressed at
postsynaptic level in the spinal cord [26]. The spinal
administration of morphine together with tertiapin-Q, a
GIRK channel blocker, dose-dependently inhibited the
analgesic effect induced by the opioid receptor agonist,
being necessary smaller doses of tertiapin-Q to avoid the
effect of morphine in osteosarcoma-bearing mice. Thus,
it could be thought that the activation of a lower number
of GIRK channels is enough to evoke analgesia in
osteosarcoma-bearing mice, suggesting an increased
efficacy of these channels. Because a relationship has
been established between the activation of NMDA
receptors and an increased presence of GIRK2 channels
in the cell surface of cultured hippocampal neurons [27],
it could be speculated that a change in GIRK efficacy
could follow the activation of spinal NMDA receptors,
which has been previously demonstrated in osteosar-
coma-bearing mice [28]. However, it does not seem easy
to explain why this mechanism does not participate in
the bone cancer model owing to the inoculation of
melanoma cells in which NMDA receptors probably play
a role. The scarce information related to the spinal
alterations owing to the intraosteal inoculation of B16-
F10 cells makes difficult to speculate about the reasons
underlying the different results produced by morphine in
both tumoral models. It has been previously described
that the expression of some spinal markers of pain such
as c-Fos or dynorphin is similar after intrafemoral NCTC
2472 or B16-F10 cell inoculation in immunodeficient
mice, whereas a marked difference appears in the
intensity of spinal astrogliosis, significantly greater in
the osteosarcoma model [29]. In any case, a hypothetical
link between increased astrogliosis and the enhancement
of morphine effects seems unlikely because, indeed, glial
activity is related to the diminution of opioid analgesia
[30]. Thus, additional data seem necessary to offer a
more comprehensive explanation for the different
potency of morphine in mice inoculated with NCTC
2472 or B16-F10 cells.
In conclusion, our data indicate that the analgesic
effect evoked by morphine on thermal nociception can be
enhanced in particular types of experimental bone
tumors, such as that produced by the intraosteal
inoculation of NCTC 2472 cells, remaining unmodified
after the inoculation of B16-F10 cells. Because these
data related to thermal analgesia suggest that some
transductional mechanisms can be altered in the sense of
potentiation, the idea that morphine is less efficacious in
experimental bone cancer models does not seem a
general rule. The spinal mechanisms involved in the
potentiation of morphine in the osteosarcoma are rather
similar to those previously described after acute inflam-
mation. Thus, although a lesser potentiation of the Gi/
o-protein-mediated analgesic effect triggered by masto-
paran appeared in NCTC 2472 inoculated mice, the
increased efficacy of spinal postsynaptic GIRK channels
8
and not presynaptic calcium channels seems implicated
in the potentiation of morphine-induced analgesia in
both experimental situations.
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